Business
PharmAla Partners with Veridion Group as Exclusive Distributor in New Zealand
TORONTO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has signed a distribution agreement with Veridion Group (“Veridion”) of New Zealand, to act as exclusive distribution agent for its LaNeo MDMA in the Netherlands market. “With the approval of the firs
About this update from Pharmala Biotech Holdings, Inc.
[{"type":"image","alt":"PharmAla Biotech","displaySize":"","headline":null,"caption":"PharmAla Biotech","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":167,"url":"https://media.zenfs.com/en/globenewswire.com/cb13b9b085f29f720752eaaea7cf9866"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Rh7A3yGxrk9MQDPQWu1yYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cb13b9b085f29f720752eaaea7cf9866","width":300,"height":167}},"lazy":false},{"type":"text","content":"TORONTO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has signed a distribution agreement with Veridion Group (“Veridion”) of New Zealand, to act as exclusive distribution agent for its LaNeo MDMA in the Netherlands market.","length":469,"tagName":"p"},{"type":"text","content":"“With the approval of the first Authorized Prescriber for Psilocybin by Medsafe – the New Zealand Medicines and Medical Devices Safety Authority – we immediately saw a number of eminent clinicians express a desire to do the same for MDMA,” said Nick Kadysh, CEO, PharmAla Biotech. “We’re incredibly pleased to have partnered with Veridion to act as our exclusive distributor for New Zealand. Veridion has the expertise we look for in a partner: executing complex operations with controlled pharmaceuticals, and working with doctors to provide exceptional care. Kia ora!”","length":570,"tagName":"p"},{"type":"text","content":"The distribution agreement includes an annual purchase minimum (waived for the first year), as well as restrictions on re-export. PharmAla anticipates shipping to New Zealand from existing inventory allocated for its Australian operations.","length":239,"tagName":"p"},{"type":"text","content":"“This partnership with PharmAla is a natural fit. Veridion has built its reputation on handling complex, highly regulated medicines, and PharmAla brings both the science and the track record to match,” said Courtney Letica, CEO, Veridion Group. “Together, we can give New Zealand clinicians confidence that when MDMA treatments become available, access will be safe, controlled, and delivered to the ...